SCHEMBL2246284

SCHEMBL2246284

Cc1cccc(NS(=O)(=O)c2ccc(NC3=C(Cl)C(=O)c4ccccc4C3=O)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.61
KMT2A Q03164 10/20 0.61
HTT P42858 10/20 0.61
MEN1 O00255 8/20 0.61
RAB9A P51151 8/20 0.61
NPC1 O15118 5/20 0.61
MITF O75030 2/20 0.61
ALDH1A1 P00352 5/20 0.60
HPGD P15428 3/20 0.60
PSMB1 P20618 2/20 0.60
PSMB5 P28074 2/20 0.60
PSMB2 P49721 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
TCF4 P15884 1/20 0.60
ALOX15 P16050 1/20 0.60
ALOX12 P18054 1/20 0.60
CYP2C19 P33261 1/20 0.60
CTNNB1 P35222 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241087 0.88 MAPT (0.76) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2241314 0.86 KMT2A (0.71) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2241338 0.85 ALDH1A1 (0.59) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2237410 0.82 MEN1 (0.55) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL18424314 0.81 CYP19A1 (0.66) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2242640 0.81 ALDH1A1 (0.62) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2243299 0.80 ALDH1A1 (0.61) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL20971703 0.80 ALDH1A1 (0.64) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL2243450 0.80 ALDH1A1 (0.64) MAPTKMT2AHTTMEN1RAB9A
SCHEMBL12352048 0.79 MAPT (0.61) MAPTKMT2AHTTMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-8673910-B2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE (US) 2014-03-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201609-A1 PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS PSMB7, PSMD7, PSMB6 MAPT 4401/4885KMT2A 2094/4885HTT 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.